Literature DB >> 11378835

The PANDORA project: results of the cost of illness analysis.

E Degli Esposti1, P Berto, P Ruffo, S Buda, L Degli Esposti, A Sturani.   

Abstract

AIMS: To evaluate the cost of illness from hypertension for the Italian National Health System (NHS). METHODS AND
RESULTS: A prospective analysis was carried out on clinical and economic data recorded in the general practitioners' (GPs) database. Twenty-one GPs working in the Ravenna area in Italy took part in the project on a voluntary basis. The study included 1047 hypertensive patients enrolled between 1 June and 31 December 1997 and continued for 365 days from the date of enrolment. The following costs were calculated: antihypertensive drugs, laboratory tests and instrumental procedures, GP visits for blood pressure control, specialist visits, casualty visits, hospitalisation due to cardiovascular problems. In the whole sample, the most relevant cost is due to antihypertensive drugs (42.7%), followed by hospital admission (28.4%), GP visits (15.1%) and tests (10.6%). The total mean cost was significantly lower in incident (no previous treatment) than in prevalent patients (already treated) (457 512 vs 725 573 Italian Lira (ITL), P < 0.05) and in older rather than in younger patients (1171 410 vs 796 452 (ITL) P < 0.05). (In the text the equivalent is given in Euros, Pounds Sterling and US dollars).
CONCLUSION: Our study should be considered as preliminary, nevertheless it could represent a step towards the evaluation of the true cost of hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378835     DOI: 10.1038/sj.jhh.1001178

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  4 in total

Review 1.  A review of the cost of cardiovascular disease.

Authors:  Jean-Eric Tarride; Morgan Lim; Marie DesMeules; Wei Luo; Natasha Burke; Daria O'Reilly; James Bowen; Ron Goeree
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

2.  Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model.

Authors:  Jürgen Scholze; Eduardo Alegria; Claudio Ferri; Sue Langham; Warren Stevens; David Jeffries; Kerstin Uhl-Hochgraeber
Journal:  BMC Public Health       Date:  2010-09-02       Impact factor: 3.295

3.  Expenditures of medicine use in hypertensive/diabetic elderly and physical activity and engagement in walking: cross secctional analysis of SABE Survey.

Authors:  Denise Rodrigues Bueno; Maria de Fátima Nunes Marucci; Luis Alberto Gobbo; Manuela de Almeida-Roediger; Yeda Aparecida de Oliveira Duarte; Maria Lucia Lebrão
Journal:  BMC Geriatr       Date:  2017-03-20       Impact factor: 3.921

4.  Economic aspects of hypertension treatment in Poland.

Authors:  Jana Krzysztoszek; Dorota Koligat; Piotr Ratajczak; Wiesław Bryl; Maciej Cymerys; Karolina Hoffmann; Ewelina Wierzejska; Paweł Kleka
Journal:  Arch Med Sci       Date:  2013-01-21       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.